Predictors of aggressive inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 7, Issue 10, 2011, Pages 652-659

  Yarur, Andres J ^a   Strobel, Sebastian G ^a   Deshpande, Amar R ^a   Abreu, Maria T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Crohn's disease; Natural history; Predictor; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; CASPASE RECRUITMENT DOMAIN PROTEIN 15;

CLINICAL FEATURE; COLON CANCER; COLON RESECTION; CROHN DISEASE; DEMOGRAPHY; ENDOSCOPY; ENTERITIS; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENE MUTATION; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; PREDICTION; PREDICTOR VARIABLE; REVIEW; SEROLOGY; SMOKING; STOMACH ULCER; ULCERATIVE COLITIS;

EID: 81155128358     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
2. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936. (Pubitemid 351451967)
3. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
4. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125. (Pubitemid 41025906)
5. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250. (Pubitemid 34784976)
6. Lichtenstein G, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006;101:1030-1038. (Pubitemid 43725317)
7. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 2009;104:2080-2088.
8. Gupta N, Cohen S, Bostrom A, et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology. 2006;130:1069-1077.
9. Lee J, Cheon J, Moon C, et al. Do patients with ulcerative colitis diagnosed at a young age have more severe disease activity than patients diagnosed when older? Digestion. 2010;81:237-243.
10. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114-1122.
11. Solberg IC, Vatn MH, Høie O, et al. IBSEN Study Group. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430-1438. (Pubitemid 350181602)
12. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656. (Pubitemid 43374514)
13. Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn's disease comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953-961.
14. Romberg-Camps M, Dagnelie P, Kester A, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104:371-383.
15. Roth LS, Chande N, Ponich T, Roth ML, Gregor J. Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. World J Gastroenterol. 2010;16:232-236.
16. Etchevers M, Aceituno M, García-Bosch O, et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis. 2009;15:1320-1325.
17. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483-489.
18. Karvellas CJ, Fedorak RN, Hanson J, Wong CK. Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Can J Gastroenterol. 2007;21:443-446. (Pubitemid 47307716)
19. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228-1233. (Pubitemid 20366527)
20. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128. (Pubitemid 46806219)
21. Siegel CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therap Adv Gastroenterol. 2009;2:245-251.
22. Page MJ, Poritz LS, Kunselman SJ, Koltun WA. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg. 2002;6:606-613. (Pubitemid 40433515)
23. Jürgens M, Laubender R, Hard F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811-1819.
24. Vavricka S, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110-119.
25. Bernstein C, Blanchard J, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-1122. (Pubitemid 32319146)
26. Yüksel I, Ataseven H, Başar Ö, et al. Peripheral arthritis in the course of inflammatory bowel diseases. Dig Dis Sci. 2011;56:183-187.
27. Goldman C, Kodner I, Fry R, MacDermott RP. Clinical and operative experience with non-Caucasian patients with Crohn's disease. Dis Colon Rectum. 1986;29:317-321. (Pubitemid 16122258)
28. Simsek H, Schuman BM. Inflammatory bowel disease in 64 black patients: analysis of course, complications, and surgery. J Clin Gastroenterol. 1989;11:294-298. (Pubitemid 19147257)
29. Nguyen G, Torres E, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic whites: characterization of a large Norm American cohort. Am J Gastroenterol. 2006;101:1012-1023. (Pubitemid 43725315)
30. Cross R, Jung C, Wasan S, Joshi G, Sawyer R, Roghmann MC. Racial differences in disease phenotypes in patients with Crohn's disease. Inflamm Bowel Dis. 2006;12:192-198.
31. Flasar M, Quezada S, Bijpuria P, Cross RK. Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study. Dig Dis Sci. 2008;53:2754-2760.
32. Straus W, Eisen G, Sandler R, et al. Crohn's disease: does race matter? The Mid-Atlantic Crohn's Disease Study Group. Am J Gastroenterol. 2000;95:479-483.
33. Jackson JF, Kornbluth A. Do black and Hispanic Americans with inflammatory bowel disease (IBD) receive inferior care compared with white Americans? Uneasy questions and speculations. Am J Gastroenterol. 2007;102:1343-1349. (Pubitemid 46976311)
34. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TI, Binder V Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324:84-88.
35. Halfvarson J. Genetics in twins with Crohn's disease: less pronounced than previously believed? Inflamm Bowel Dis. 2010;17:6-12.
36. Bayless TM, Tokayer AZ, Polito JM 2nd, Quaskey SA, Mellits ED, Harris ML. Crohn's disease: concordance for site and clinical type in affected family members - potential hereditary influences. Gastroenterology. 1996;111:573-579. (Pubitemid 26293219)
37. Henriksen M, Jahnsen J, Lygren I, Vatn MH, Mourn B; IBSEN Study Group. Are there any differences in phenotypc or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. Am J Gastroenterol. 2007;102:1955-1963. (Pubitemid 47301533)
38. Haritunians T, Taylor K, Targan S, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:1830-1840.
39. Halme L, Turunen U, Helio T, et al. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol. 2002;37:692-698. (Pubitemid 34620932)
40. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008;43:948-954.
41. Papi C, Festa V, Fagnani C, et al. Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. Dtg Liver Dis. 2005;37:247-253. (Pubitemid 41070522)
42. Chow DK, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis. 2009;15:551-557.
43. Bataille F, Klebl F, Rümmele P, et al. Histopathological parameters as predictors for the course of Crohn's disease. Virchows Arch. 2003;443:501-507. (Pubitemid 37363376)
44. Mueller MH, Geis M, Glatzle J, et al. Risk of fecal diversion in complicated perianal Crohn's disease. J Gastrointest Surg. 2007;11:529-537.
45. Lecomte T, Contou JF, Beaugerie L, et al. Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine. Dis Colon Rectum. 2003;46:1469-1475. (Pubitemid 37429726)
46. Papi C, Festa V, Leandro G, et al. Long-term outcome of Crohn's disease following corticosteroid-induced remission. Am J Gastroenterol. 2007;102:814-819. (Pubitemid 46496609)
47. Krupoves A, Mack DR, Seidman EG, Deslandres C, Bucionis V, Amre DK. Immediate and long-term outcomes of corticosteroid therapy in pediatric Crohn's disease patients. Inflamm Bowel Dis. 2011;17:954-962.
48. Sands B, Arsenault J, Rosen M, et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003;98:2712-2718. (Pubitemid 38020113)
49. Oriuchi T, Hiwatashi N, Kinouchi Y, et al. Clinical course and longterm prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation, and mortality. J Gastroenterol. 2003;38:942-953. (Pubitemid 37455781)
50. Farmer R, Easley K, Rankin G. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137-1146. (Pubitemid 23175139)
51. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422. (Pubitemid 47187355)
52. Rioux K. What is the prognosis of ulcerative colitis? Inflamm Bowel Dis. 2008;14:S52-S53.
53. Allez M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol. 2010;16:2626-2632.
54. Carbonnel F, Lavergne A, Lémann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci. 1994;39:1550-1557. (Pubitemid 24246449)
55. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079-1087. (Pubitemid 38703520)
56. Lau A, Chande N, Ponich T, Gregor JC. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2008;28:606-613.
57. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543-550. (Pubitemid 43977734)
58. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295-1301.
59. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:855-862. (Pubitemid 30663897)
60. Lindberg E, Järnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. Gut. 1992;33:779-782.
61. Cottone M, Scimeca D, Mocciaro F, Civitavecchia G, Perricone G, Orlando A. Clinical course of ulcerative colitis. Dig Liver Dis. 2008;40(suppl 2):S247-S252. (Pubitemid 351878067)
62. Russel MG, Nieman FH, Bergers JM, Stockbrügger RW. Cigarette smoking and quality of life in patients with inflammatory bowel disease. South Limburg IBD Study Group. Eur J Gastroenterol Hepatol. 1996;8:1075-1081. (Pubitemid 26383865)
63. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology. 2001;120:1093-1099. (Pubitemid 32246663)
64. van der Heide F, Dijkstra A, Weersma RK, et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2009;15:1199-1207.
65. van der Heide F, Wassenaar M, van der Linde K, Spoelstra P, Kleibeuker JH, Dijkstra G. Effects of active and passive smoking on Crohn's disease and ulcerative colitis in a cohort from a regional hospital. Eur J Gastroenterol Hepatol. 2011;23:255-261.
66. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20. (Pubitemid 32061864)
67. Benoni C, Nilsson A. Smoking habits in patients with inflammatory bowel disease. A case-control study. Scand J Gastroenterol. 1987;22:1130-1136. (Pubitemid 17157010)
68. Domènech E, Carrión S, Garcia-Planella E, et al. Smoking status and response to thiopurines in steroid-dependent inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:971-975.
69. Joelsson M, Benoni C, Oresland T. Does smoking influence the risk of pouchitis following ileal pouch anal anastomosis for ulcerative colitis? Scand J Gastroenterol. 2006;41:929-933. (Pubitemid 43995468)
70. Yarur AJ, Sussman DA, Deshpande AR, et al. Neutrophil-to-lymphocyte ratio as a predictor of surgical complications in inflammatory bowel disease. Gastroenterology. 2011;140(suppl 1):S-436.
71. Radford-Smith G, Edwards J, Purdie D, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut. 2002;51:808-813. (Pubitemid 35408600)
72. Riegler G, Caserta L, Esposito I, et al. Worse clinical course of disease in Crohn's patients with previous appendectomy. Eur J Gastroenterol Hepatol. 2005;17:623-627. (Pubitemid 40733809)
73. Kaplan GG, Pedersen BV, Andersson RE, Sands BE, Korzenik J, Frisch M. The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut. 2007;56:1387-1392. (Pubitemid 47517832)
74. Cosnes J, Seksik P, Nion-Larmurier I, Beaugerie L, Gendre JP. Prior appendectomy and the phenotype and course of Crohn's disease. World J Gastroenterol. 2006;12:1235-1242.
75. Andersson R, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001;344:808-814. (Pubitemid 32222158)
76. Cosnes J, Carbonnel F, Beaugerie L, Blain A, Reijasse D, Gendre JP. Effects of appendicectomy on the course of ulcerative colitis. Gut. 2002;51:803-807. (Pubitemid 35408599)
77. Timmer A, Sutherland L, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology. 1998;114:1143-1150. (Pubitemid 28243899)
78. Wakefield AJ, Sawyerr AM, Hudson M, Dhillon AP, Pounder RE. Smoking, the oral contraceptive pill, and Crohn's disease. Dig Dis Sci. 1991;36:1147-1150.
79. Heresbach D, Alexandre JL, Branger B, et al. Frequency and significance of granulomas in a cohort of incident cases of Crohn's disease. Gut. 2005;54:215-222. (Pubitemid 40139236)
80. Cook MG, Dixon MF. An analysis of the reliability of detection and diagnostic value of various pathological features in Crohn's disease and ulcerative colitis. Gut. 1973;14:255-262.
81. Freeman HJ. Granuloma-positive Crohn's disease. Can J Gastroenterol. 2007;21:583-587. (Pubitemid 350011442)
82. Markowitz J, Kahn E, Daum F. Prognostic significance of epithelioid granulomas found in rectosigmoid biopsies at the initial presentation of pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 1989;9:182-186. (Pubitemid 19210210)
83. Melson JE, Giusto D, Kwasny M, Eichenscer P, Jakate S, Keshavarzian A. Histopathology predictors of medically refractory ulcerative colitis. Dis Colon Rectum. 2010;53:1280-1286.
84. Yantiss RK, Sapp HL, Farraye FA, et al. Histologic predictors of pouchitis in patients with chronic ulcerative colitis. Am J Surg Pathol. 2004;28:999-1006. (Pubitemid 38971423)
85. Devlin SM, Dubinsky MC. Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Inflamm Bowel Dis. 2008;14:125-128. (Pubitemid 351196877)
86. Abreu MT. Serologies in Crohn's disease: can we change the gray zone to black and white? Gastroenterology. 2006;131:664-667. (Pubitemid 44142478)
87. Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010;28:418-423.
88. Palmon R, Brown SJ, Abreu MT. What is the role and significance of serum and stool biomarkers in the diagnosis of IBD? Inflamm Bowel Dis. 2008;14(suppl 2):S187-S189.
89. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394-1403. (Pubitemid 47517833)
90. Mow W, Vasiliauskas E, Lin Y, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424. (Pubitemid 38182298)
91. Vasiliauskas EA, Kam L, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-496.
92. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6:1105-1111.
93. Turkcapar N, Toruner M, Soykan I, et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int. 2006;26:663-668.
94. Fleshner P, Ippoliti A, Dubinsky M, et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6:561-568.
95. Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut. 2001;49:671-677. (Pubitemid 32989204)
96. Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lémann M, Mary JY; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis. 2006;12:551-557. (Pubitemid 43977735)
97. Henriksen M, Jahnsen J, Lygren I, et al. IBSEN Study Group. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518-1523.
98. Moore JC, Thompson K, Lafleur B, et al. Clinical variables as prognostic tools in pediatric-onset ulcerative colitis: a retrospective cohort study. Inflamm Bowel Dis. 2011;17:15-21.
99. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis. 2005;11:589-596. (Pubitemid 40826347)
100. Nishio Y, Ando T, Maeda O, et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut. 2006;55:1768-1773. (Pubitemid 44893576)
101. Reinisch W, Gasché C, Tillinger W, et al. Clinical relevance of scrum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol. 1999;94:2156-2164. (Pubitemid 29374547)
102. Van Kemseke C, Belaiche J, Louis E. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor scrum levels during remission. Int J Colorectal Dis. 2000;15:206-210.
103. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;25:247-255.
104. Tibbie JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel diseases. Gastroenterology. 2000;119:15-22. (Pubitemid 30452574)
105. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190-1198.
106. Czub E, Herzig KH, Szaflarska-Popawska A, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1147-1150. (Pubitemid 47537095)
107. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847-853. (Pubitemid 36613492)
108. Halfvarson J, Bodin L, Tysk C, Lindberg E, Järnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003;124:1767-1773. (Pubitemid 36666773)
109. Van Limbergen J, Russell RK, Nimmo ER, Satsangi J. The genetics of inflammatory bowel disease. Am J Gastroenterol. 2007;102:2820-2831. (Pubitemid 350179337)
110. Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol. 2009;7:972-980.
111. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002;359:1661-1665. (Pubitemid 34518526)
112. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122:854-866. (Pubitemid 34267267)
113. Seiderer J, Brand S, Herrmann KA, et al. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. Inflamm Bowel Dis. 2006;12:1114-1121. (Pubitemid 44847468)
114. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688. (Pubitemid 34977073)
115. Weersma RK, Stokkers PC, van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut. 2009;58:388-395.
116. Mizushima N, Kuma A, Kobayashi Y, et al. Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate. J Cell Sci. 2003;116(pt 9):1679-1688. (Pubitemid 36582155)
117. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207-1212.
118. Ho G, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut. 2003;52:759-766. (Pubitemid 36528884)
119. Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 2004;5:530-539. (Pubitemid 39529969)
120. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612-1619.